Is XTLB or ZNTL more undervalued in 2026?

CirclFi compares XTL Biopharmaceuticals Ltd. (XTLB) and Zentalis Pharmaceuticals, Inc. (ZNTL) using 13 institutional-grade valuation models. XTLB has a Quality of Company score of 1.7/10 while ZNTL scores 5.0/10.

Which is a better buy — XTLB or ZNTL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do XTLB and ZNTL valuations compare?

XTLB at $2.46 and ZNTL at $4.05 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

XTLB vs ZNTL Valuation Comparison 2026 — Intrinsic Value Analysis

XTLB

Biotechnology

XTL Biopharmaceuticals Ltd.

Quality

1.7

out of 10

Value Trap

—

Price

$2.46

Last close

Models

6/13

Active

ZNTL

Biotechnology

Zentalis Pharmaceuticals, Inc.

Quality

5.0

out of 10

Value Trap

SAFE

Price

$4.05

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	XTLB Fair Value	XTLB Upside	ZNTL Fair Value	ZNTL Upside
Bayesian DCF	Intrinsic	$0.65	-73.5%	$1.11	-72.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	—	—	$2.99	-26.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$0.72	-71.6%	$2.01	-50.3%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for XTLB vs ZNTL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XTLB vs ZNTL — Which Stock Is More Undervalued?

ZNTL scores higher with a 5.0/10 quality rating vs XTLB's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing XTL Biopharmaceuticals Ltd. (XTLB) and Zentalis Pharmaceuticals, Inc. (ZNTL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XTLB currently trades at $2.46 with a QOC of 1.7/10, while ZNTL trades at $4.05 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).